Your browser doesn't support javascript.
loading
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.
Lambert-Niclot, Sidonie; Abdi, Basma; Bellet, Jonathan; Fofana, Djeneba; De Truchis, Pierre; Amat, Karine; Alvarez, Jean-Claude; Surgers, Laure; Allavena, Clothilde; Zaegell-Faucher, Olivia; Morlat, Philippe; Palich, Romain; Gibowski, Séverine; Costagliola, Dominique; Girard, Pierre-Marie; Landman, Roland; Assoumou, Lambert; Morand-Joubert, Laurence.
Affiliation
  • Lambert-Niclot S; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), 184 rue du Faubourg Saint-Antoine, 75571 Cedex 12, Paris, France.
  • Abdi B; AP-HP Hôpital Saint-Antoine, Laboratoire de Virologie, Paris, France.
  • Bellet J; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), 184 rue du Faubourg Saint-Antoine, 75571 Cedex 12, Paris, France.
  • Fofana D; AP-HP Hôpital Pitié-Salpêtrière, Virology Department, Paris, France.
  • De Truchis P; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), 184 rue du Faubourg Saint-Antoine, 75571 Cedex 12, Paris, France.
  • Amat K; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), 184 rue du Faubourg Saint-Antoine, 75571 Cedex 12, Paris, France.
  • Alvarez JC; AP-HP Hôpital Saint-Antoine, Laboratoire de Virologie, Paris, France.
  • Surgers L; Hôpitaux Universitaires Paris-Ile de France-Ouest, Hôpital Raymond Poincaré APHP, Université Versailles-Saint-Quentin, France, Infectious Diseases Department, Garches, France.
  • Allavena C; Institut de Médecine et Epidémiologie Appliquée, Hôpital Bichat, Université Paris 7, Paris, France.
  • Zaegell-Faucher O; Département de Pharmacologie-Toxicologie, Hôpital R Poincaré APHP, Inserm U-1173, Université Versailles-Saint-Quentin, Garches, France.
  • Morlat P; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), 184 rue du Faubourg Saint-Antoine, 75571 Cedex 12, Paris, France.
  • Palich R; GHU APHP. Sorbonne Université, Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, F75012, Paris, France.
  • Gibowski S; Hôpital Hôtel-Dieu, Infectious Diseases Department, Nantes, France.
  • Costagliola D; CHU Sainte-Marguerite, Assistance Publique Hôpitaux de Marseille, Infectious Diseases Department, Marseille, France.
  • Girard PM; Hôpital Saint André, Internal Medicine and Infectious Diseases Department, CHU, Université de Bordeaux, Bordeaux, France.
  • Landman R; AP-HP Hôpital Pitié-Salpêtrière, Infectious Diseases Department, Paris, France.
  • Assoumou L; ANRS, MIE Maladies Infectieuses Emergentes, Paris, France.
  • Morand-Joubert L; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), 184 rue du Faubourg Saint-Antoine, 75571 Cedex 12, Paris, France.
J Antimicrob Chemother ; 78(6): 1510-1521, 2023 06 01.
Article in En | MEDLINE | ID: mdl-37104815
ABSTRACT

BACKGROUND:

In a 4 days/week (4/7 days) maintenance strategy (ANRS-170 QUATUOR trial), the virological impact of an intermittent strategy was assessed by ultrasensitive virological analyses of reservoirs and resistance.

METHODS:

HIV-1 total DNA, ultra-sensitive plasma viral load (USpVL) and semen VL were measured in the first 121 participants. Sanger and ultra-deep sequencing (UDS) were performed on the HIV-1 genome (Illumina technology) according to the ANRS consensus. A generalized estimation equation with a Poisson distribution was used to compare changes in the proportion of residual viraemia, detectable semen HIV RNA and HIV DNA within and between the two groups over time.

RESULTS:

The proportion of participants with residual viraemia at Day 0 (D0) and Week 48 (W48) was 16.7% and 25.0% in the 4/7 days group and 22.4% and 29.7% in the 7/7 days group, respectively (+8.3% versus +7.3%, P = 0.971). The proportion of detectable DNA (>40 copies/106 cells) at D0 and W48 was 53.7% and 57.4% in the 4/7 days group and 56.1% and 51.8% in the 7/7 days group, respectively (+3.7% versus -4.3%, P = 0.358). Semen HIV RNA was detectable (≥100 copies/mL) in 2.2% of participants at D0 and 4.5% at W48 in the 4/7 days group versus 6.1% and 9.1% in the 7/7 days group, respectively (+2.3% versus +3.0%, P = 0.743). Emerging resistance at failure was more frequent in the 4/7 days group detected by Sanger sequencing 3/6 participants versus 1/4 in the 7/7 days group, and similar with the UDS assay 5/6 versus 4/4, respectively.

CONCLUSIONS:

These findings support the potency of a 4/7 days maintenance strategy on virological suppression at the reservoirs and emergent resistance level, including minority variants.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents Limits: Humans Language: En Journal: J Antimicrob Chemother Year: 2023 Type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents Limits: Humans Language: En Journal: J Antimicrob Chemother Year: 2023 Type: Article Affiliation country: France